An Open-Label, Single-Arm, Multicenter Phase 2/3b Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma Habouring FGFR2 Fusion/Rearrangement
Latest Information Update: 04 Sep 2026
At a glance
- Drugs Fanregratinib (Primary)
- Indications Cholangiocarcinoma
- Focus First in man; Registrational; Therapeutic Use
- Sponsors Hutchison MediPharma; HUTCHMED
Most Recent Events
- 04 Sep 2026 According to a HUTCHMED media release, the New Drug Application (NDA) for fanregratinib (HMPL-453) has been granted conditional approval by the China National Medical Products Administration (NMPA) for the treatment of adult patients with advanced, metastatic or unresectable intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusion or rearrangement who have previously received systemic therapy.
- 25 Jun 2026 Results presented in a HUTCHMED media release.
- 25 Jun 2026 According to a HUTCHMED media release, data from this study will be presented at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress taking place from July 1 to 4, 2026 in Munich, Germany.